Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin

Gefapixant (MK‐7264, AF‐219), a first‐in‐class P2X3 antagonist, is being developed as oral treatment for refractory or unexplained chronic cough. Based on in vitro data, gefapixant exerts inhibitory activity on the organic anion transporter (OAT) P1B1 transporter. Therefore, a drug‐drug interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrea, Jacqueline B., Hussain, Azher, Ma, Bennett, Garrett, Graigory C., Evers, Raymond, Laabs, John E., Stoch, S. Aubrey, Iwamoto, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298894/
https://www.ncbi.nlm.nih.gov/pubmed/34821075
http://dx.doi.org/10.1002/cpdd.1047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298894/
https://www.ncbi.nlm.nih.gov/pubmed/34821075
http://dx.doi.org/10.1002/cpdd.1047

Ejemplares similares